Therapy Areas: Inflammatory Diseases
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
18 June 2026 - Swedish clinical-stage pharmaceutical company Gesynta Pharma AB announced on Wednesday that 50% of the target of 190 patients have been randomised in its Phase 2 clinical proof-of-conce...
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
16 June 2026 - Hillhurst Biopharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, announced on Mond...
Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes
16 June 2026 - Clinical-stage biotechnology company Halia Therapeutics Inc announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184...
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
10 June 2026 - US healthcare company Organon (NYSE:OGN) on Wednesday announced US Food and Drug Administration (FDA) approval of a supplemental Biologics License Application for TOFIDENCE (tocilizumab...
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
10 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that it will stop the phase 3 MOBILIZE study evaluating riliprubart in patients with chron...
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
10 June 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, ...